

CRIM2 Antibody

Catalog # ASC11522

Product Information

Application	WB, E
Primary Accession	Q6ZWI8
Other Accession	NP_001129386 , 209571519
Reactivity	Human, Mouse, Rat
Host	Rabbit
Clonality	Polyclonal
Isotype	IgG
Calculated MW	166935
Concentration (mg/ml)	1 mg/mL
Conjugate	Unconjugated
Application Notes	CRIM2 antibody can be used for detection of CRIM2 by Western blot at 1 - 2 μ g/mL.

Additional Information

Gene ID	375616
Other Names	Kielin/chordin-like protein, Cysteine-rich BMP regulator 2, Cysteine-rich motor neuron 2 protein, CRIM-2, Kielin/chordin-like protein 1, KCP-1, KCP, CRIM2, KCP1
Target/Specificity	KCP; At least two isoforms of CRIM2 are known to exist; this antibody will only detect the larger isoform. CRIM2 antibody is predicted to not cross-react with CRIM1.
Reconstitution & Storage	CRIM2 antibody can be stored at 4°C for three months and -20°C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.
Precautions	CRIM2 Antibody is for research use only and not for use in diagnostic or therapeutic procedures.

Protein Information

Name	KCP (HGNC:17585)
Synonyms	CRIM2, KCP1
Function	Enhances bone morphogenetic protein (BMP) signaling in a paracrine manner. In contrast, it inhibits both the activin-A and TGFB1-mediated signaling pathways (By similarity).
Cellular Location	Secreted.

Background

CRIM2 Antibody: CRIM2, also known as Kielin/chordin-like protein (KCP), is a novel enhancer of BMP signaling. It binds to BMP7, a morphogen that is important for kidney development and part of the kidney's physiological response to repair of acute kidney injury, enhancing its binding to its receptor. Because of this, CRIM2 has been suggested as a potential antifibrotic therapy in acute and chronic kidney injury. CRIM2 can also interact directly with either activin or TGF- β 1, suppressing activin- and TGF- β 1-dependent transcription.


References

Lin J, Patel SR, Cheng X, et al. Kielin/chordin-like protein, a novel enhancer of BMP signaling, attenuates renal fibrotic disease. *Nat. Med.* 2005; 11:387-93

Zeisberg M and Kalluri R. Reversal of experimental renal fibrosis by BMP7 provides insights into novel therapeutic strategies for chronic kidney disease. *Pediatr. Nephrol.* 2008; 23:1395-8.

Lin J, Patel SR, Wang M, et al. The cysteine-rich domain protein KCP is a suppressor of transforming growth factor β /Activin signaling in renal epithelia. *Mol. Cell. Biol.* 2006; 26:4577-85.

Images



Western blot analysis of CRIM2 in Jurkat cell lysate with CRIM2 antibody at (A) 1 and (B) 2 μ g/mL.

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.